Periphagen is a biopharmaceutical company focused on the development of herpes simplex virus type I (HSV-1) as a gene therapy vector. Our primary focus is the use of HSV-1 vectors for neurologic disease but we also have extensive experience and HSV-1 vector technology available for other indications.
[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/periphagen-inc” connections=”true” suffix=””]
PeriphaGens gene delivery platform, NEuronal Therapeutics (NET) is based on a highly engineered herpes simplex virus type 1 (HSV) vector.
In 2014, PeriphaGen raised $6.5 Mn as a capital, according to a filing with the Securities and Exchange Commission. Investors were not disclosed.